Клинички испитувања за Дебелина во Мичиген
29 студии за Дебелина бараат учесници на локации во Мичиген.
Градови во Мичиген
Официјален текст на студијата (англиски)
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Revival Research Institute, LLC, Dearborn
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07783802Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- Profound Research, Farmington Hills
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 28.9.2026 · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Northern Pines Hlth Ctr, PC, Buckley
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07720271A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Aa Mrc Llc, Flint
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07595549A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Helen Devos Childrens' Hospital - PIN, Grand Rapids
Се регрутираФаза 3
Возраст од 6 до 17 · Сите полови · Ажурирано 24.9.2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Great Lakes Research Institute, Southfield
- Revive Research Institute, Inc., Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Farmington Hills
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07784270A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Revive Research Institute, Inc., Southfield
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07369011A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Headlands Research - Detroit, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 22.9.2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Southfield
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- University of Michigan Health System, Dominos Farms, Ann Arbor
- Embassy Research Network, Bloomfield Township
- Henry Ford Health System, Detroit
- и уште 3
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 16.9.2026 · NCT07037459A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Headlands Research - Detroit, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 8.9.2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- David Fivenson, MD, PLC, Ann Arbor
- The Derm Institute of West Michigan, Caledonia
Се регрутираФаза 4
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Farmington Hills
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Headlands Research - Detroit, Southfield
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 3.9.2026 · NCT07684235Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Farmington Hills
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 1.9.2026 · NCT07284979Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division, Troy
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 27.8.2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Troy
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.8.2026 · NCT07784725Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- C.S. Mott University of Michigan, Ann Arbor
Се регрутираФаза 2
Возраст од 7 до 25 · Сите полови · Ажурирано 19.8.2026 · NCT05082519A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Cardio and Vascular Assoc-CAVA, Bloomfield Hills
- Corewell Health, Grand Rapids
- University Of Michigan, Lansing
- и уште 2
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT07567001AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Arcturus Healthcare, PLC., Troy
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Ann Arbor
Се регрутираФаза 3
Возраст од 18 до 79 · Сите полови · Ажурирано 10.8.2026 · NCT07654361Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
- University of Michigan, Ann Arbor
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 15 до 75 · Сите полови · Ажурирано 13.7.2026 · NCT02043457Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
- University of Michigan, Ann Arbor
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 14 до 18 · Сите полови · Ажурирано 13.7.2026 · NCT06007404Michigan Weight Navigation Program (MiWeigh) Study
- University of Michigan, Ann Arbor
Се регрутира
Возраст од 18 до 75 · Сите полови · Ажурирано 12.6.2026 · NCT07465341Exercise Effects on Adipose Tissue Structure and Function
- University of Michigan, Ann Arbor
Се регрутира
Возраст од 18 до 40 · Сите полови · Ажурирано 4.6.2026 · NCT04812314Metabolic Adaptations to Weight Loss With and Without Exercise
- University of Michigan, Ann Arbor
Се регрутираДобредојдени се здрави волонтери
Возраст од 18 до 40 · Сите полови · Ажурирано 14.4.2026 · NCT05806801RESET System Pivotal Trial (Rev F)
- Michigan Medicine, Division of Gastroenterology and Hepatology, Ann Arbor
Се регрутира
Возраст од 22 до 65 · Сите полови · Ажурирано 18.7.2024 · NCT04101669Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.